Home › Trials › NCT06431373

Evaluating brepocitinib for adults with active non-infectious uveitis

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

Phase 3 Interventional Priovant Therapeutics, Inc. · NCT06431373

This study is testing if a new medication called brepocitinib can help adults with active non-infectious uveitis feel better and improve their eye health.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment300 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorPriovant Therapeutics, Inc. Industry-sponsored
Drugs / interventionsbrepocitinib
Locations40 sites (Phoenix, Arizona and 39 other locations)
Trial IDNCT06431373 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety and effectiveness of brepocitinib in adults suffering from active, non-infectious uveitis, specifically targeting intermediate, posterior, or pan uveitis. Participants will be randomly assigned to receive either brepocitinib or a placebo once daily. The study will include adults aged 18 to 75 years who have active disease in at least one eye and meet specific health criteria. The goal is to determine if brepocitinib can provide a beneficial treatment option for this condition.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18-75 with a diagnosis of active non-infectious uveitis.

Not a fit: Patients with infectious uveitis or those with certain recent health issues, such as malignancies or active infections, may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with non-infectious uveitis, potentially improving their quality of life.

How similar studies have performed: Other studies have explored treatments for uveitis, but the specific use of brepocitinib in this context is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult subjects (18-75 years old)
* Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
* Active uveitic disease in at least 1 eye
* Weight \> 40 kg with a body mass index ≤ 40 kg/m2

Exclusion Criteria:

Has confirmed or suspected current diagnosis of infectious uveitis History of or have:

1. Lymphoproliferative disorder
2. active malignancy
3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
4. thrombosis orand cerebrovascularardiovascular ischemic event disease within the last 12 months
5. a high risk for herpes zoster reactivation
6. active or recent infections

Where this trial is running

Phoenix, Arizona and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Uveitis, PosteriorUveitis, IntermediateUveitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.